Status:
UNKNOWN
CXCL2/CXCL8 Promote Intervertebral Disc Degeneration
Lead Sponsor:
Zhongda Hospital
Conditions:
Cytokine
Intervertebral Disc, Degenerative
Eligibility:
All Genders
Brief Summary
Low back pain (LBP) is the largest cause of morbidity in the world, and about 80% of Chinese people are affected in their lifetime. Although the prevalence of IDD gradually increases with age, IDD is ...
Eligibility Criteria
Inclusion
- It meets the diagnostic criteria of lumbar disc degeneration; No previous history of spinal surgery; Good ability of independent behavior and cooperation in completing research; The patient is aware of this study and has signed the consent form.
Exclusion
- Patients with spinal tumor, infection, tuberculosis and other diseases; Patients with claustrophobia; Parkinson's syndrome patients; Poor cooperation, Poor image quality; Patients with osteoporosis.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05976516
Start Date
August 1 2023
End Date
March 30 2024
Last Update
August 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongda Hospital
Nanjing, Jiangsu, China